Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress
Hikma Pharmaceuticals (LON:HIK) outlined a more centralized research and development strategy at the first event in its R&D Spotlight series, highlighting investments in respiratory, nasal, semi-solid and liquid products and describing its approach to developing higher-complexity medicines. Hafrun Fridriksdottir, Hikma’s global head of R&D, said the company reorganized its R&D activities into a global structure
This is a short summary. The full story is published by Zolmax.
Read full story at Zolmax
